SCOPUS 정보 검색 플랫폼

1
- 84898602820
- Changes in diabetes-related complications in the United States, 1990–2010
- Gregg, EW, Li, Y, Wang, J, et al. Changes in diabetes-related complications in the United States, 1990–2010. N Engl J Med 370 (2014), 1514–1523.
- (2014) N Engl J Med , vol.370 , pp. 1514-1523
- Gregg, E.W.¹ Li, Y.² Wang, J.³

2
- 84937216336
- Association of cardiometabolic multimorbidity with mortality
- Emerging Risk Factors Collaboration Di Angelantonio, E, Kaptoge, S, et al. Association of cardiometabolic multimorbidity with mortality. JAMA 314 (2015), 52–60.
- (2015) JAMA , vol.314 , pp. 52-60
- Di Angelantonio, E.¹ Kaptoge, S.²

3
- 84921364667
- Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people
- Shah, AD, Langenberg, C, Rapsomaniki, E, et al. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people. Lancet Diabetes Endocrinol 3 (2015), 105–113.
- (2015) Lancet Diabetes Endocrinol , vol.3 , pp. 105-113
- Shah, A.D.¹ Langenberg, C.² Rapsomaniki, E.³

4
- 85038951494
- Cardiovascular outcomes trials in type 2 diabetes: where do we go from here? Reflections from a Diabetes Care Editors' Expert Forum
- Cefalu, WT, Kaul, S, Gerstein, HC, et al. Cardiovascular outcomes trials in type 2 diabetes: where do we go from here? Reflections from a Diabetes Care Editors' Expert Forum. Diabetes Care 41 (2018), 14–31.
- (2018) Diabetes Care , vol.41 , pp. 14-31
- Cefalu, W.T.¹ Kaul, S.² Gerstein, H.C.³

5
- 84978839381
- Liraglutide and cardiovascular outcomes in type 2 diabetes
- Marso, SP, Daniels, GH, Brown-Frandsen, K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375 (2016), 311–322.
- (2016) N Engl J Med , vol.375 , pp. 311-322
- Marso, S.P.¹ Daniels, G.H.² Brown-Frandsen, K.³

6
- 84994813253
- Semaglutide and cardiovascular outcomes in patients with type 2 diabetes
- Marso, SP, Bain, SC, Consoli, A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375 (2016), 1834–1844.
- (2016) N Engl J Med , vol.375 , pp. 1834-1844
- Marso, S.P.¹ Bain, S.C.² Consoli, A.³

7
- 85055101508
- Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
- Hernandez, AF, Green, JB, Janmohamed, S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 392 (2018), 1519–1529.
- (2018) Lancet , vol.392 , pp. 1519-1529
- Hernandez, A.F.¹ Green, J.B.² Janmohamed, S.³

8
- 85044600598
- Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis
- Bethel, MA, Patel, RA, Merrill, P, et al. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol 6 (2018), 105–113.
- (2018) Lancet Diabetes Endocrinol , vol.6 , pp. 105-113
- Bethel, M.A.¹ Patel, R.A.² Merrill, P.³

9
- 85059501499
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- Zelniker, TA, Wiviott, SD, Raz, I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393 (2019), 31–39.
- (2019) Lancet , vol.393 , pp. 31-39
- Zelniker, T.A.¹ Wiviott, S.D.² Raz, I.³

10
- 85066483412
- Canagliflozin and renal outcomes in type 2 diabetes and nephropathy
- published online April 14.
- Perkovic, V, Jardine, MJ, Neal, B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med, 2019 published online April 14. DOI:10.1056/NEJMoa1811744.
- (2019) N Engl J Med
- Perkovic, V.¹ Jardine, M.J.² Neal, B.³

11
- 85044712523
- Pharmacologic glycemic management of type 2 diabetes in adults
- Diabetes Canada Clinical Practice Guidelines Expert Committee Lipscombe, L, Booth, G, et al. Pharmacologic glycemic management of type 2 diabetes in adults. Can J Diabetes 42:suppl 1 (2018), S88–S103.
- (2018) Can J Diabetes , vol.42 , pp. S88-S103
- Lipscombe, L.¹ Booth, G.²

12
- 85058738504
- 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2019
- American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2019. Diabetes Care 42:suppl 1 (2019), S90–S102.
- (2019) Diabetes Care , vol.42 , pp. S90-S102

13
- 84969988486
- Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program
- Jendle, J, Grunberger, G, Blevins, T, Giorgino, F, Hietpas, RT, Botros, FT, Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program. Diabetes Metab Res Rev 32 (2016), 776–790.
- (2016) Diabetes Metab Res Rev , vol.32 , pp. 776-790
- Jendle, J.¹ Grunberger, G.² Blevins, T.³ Giorgino, F.⁴ Hietpas, R.T.⁵ Botros, F.T.⁶

14
- 84953898275
- Efficacy and safety of dulaglutide in patients with type 2 diabetes: a meta-analysis and systematic review
- Zhang, L, Zhang, M, Zhang, Y, Tong, N, Efficacy and safety of dulaglutide in patients with type 2 diabetes: a meta-analysis and systematic review. Sci Rep, 6, 2016, 18904.
- (2016) Sci Rep , vol.6
- Zhang, L.¹ Zhang, M.² Zhang, Y.³ Tong, N.⁴

15
- 85048436169
- Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial
- Tuttle, KR, Lakshmanan, MC, Rayner, B, et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol 6 (2018), 605–617.
- (2018) Lancet Diabetes Endocrinol , vol.6 , pp. 605-617
- Tuttle, K.R.¹ Lakshmanan, M.C.² Rayner, B.³

16
- 85053841353
- Glucagon-like peptide-1 receptor action in the vasculature
- Almutairi, M, Al Batran, R, Ussher, JR, Glucagon-like peptide-1 receptor action in the vasculature. Peptides 111 (2019), 26–32.
- (2019) Peptides , vol.111 , pp. 26-32
- Almutairi, M.¹ Al Batran, R.² Ussher, J.R.³

17
- 85023614886
- Design and baseline characteristics of participants in the Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide
- Gerstein, HC, Colhoun, HM, Dagenais, GR, et al. Design and baseline characteristics of participants in the Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide. Diabetes Obes Metab 20 (2018), 42–49.
- (2018) Diabetes Obes Metab , vol.20 , pp. 42-49
- Gerstein, H.C.¹ Colhoun, H.M.² Dagenais, G.R.³

18
- 33747120659
- Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate
- Levey, AS, Coresh, J, Greene, T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145 (2006), 247–254.
- (2006) Ann Intern Med , vol.145 , pp. 247-254
- Levey, A.S.¹ Coresh, J.² Greene, T.³

19
- 84859840957
- Designing and analyzing clinical trials with composite outcomes: consideration of possible treatment differences between the individual outcomes
- Pogue, J, Devereaux, PJ, Thabane, L, Yusuf, S, Designing and analyzing clinical trials with composite outcomes: consideration of possible treatment differences between the individual outcomes. PLoS One, 7, 2012, e34785.
- (2012) PLoS One , vol.7
- Pogue, J.¹ Devereaux, P.J.² Thabane, L.³ Yusuf, S.⁴

20
- 0003831001
- Group sequential methods with applications to clinical trials
- Chapman & Hall/CRC Boca Raton
- Jennison, C, Turnbull, BW, Group sequential methods with applications to clinical trials. 2000, Chapman & Hall/CRC, Boca Raton.
- (2000)
- Jennison, C.¹ Turnbull, B.W.²

21
- 84892484110
- Advanced multiplicity adjustment methods in clinical trials
- Alosh, M, Bretz, F, Huque, M, Advanced multiplicity adjustment methods in clinical trials. Stat Med 33 (2014), 693–713.
- (2014) Stat Med , vol.33 , pp. 693-713
- Alosh, M.¹ Bretz, F.² Huque, M.³

22
- 80755127019
- Graphical approaches for multiple comparison procedures using weighted Bonferroni, Simes, or parametric tests
- Bretz, F, Posch, M, Glimm, E, Klinglmueller, F, Maurer, W, Rohmeyer, K, Graphical approaches for multiple comparison procedures using weighted Bonferroni, Simes, or parametric tests. Biom J 53 (2011), 894–913.
- (2011) Biom J , vol.53 , pp. 894-913
- Bretz, F.¹ Posch, M.² Glimm, E.³ Klinglmueller, F.⁴ Maurer, W.⁵ Rohmeyer, K.⁶

23
- 60749089513
- A graphical approach to sequentially rejective multiple test procedures
- Bretz, F, Maurer, W, Brannath, W, Posch, M, A graphical approach to sequentially rejective multiple test procedures. Stat Med 28 (2009), 586–604.
- (2009) Stat Med , vol.28 , pp. 586-604
- Bretz, F.¹ Maurer, W.² Brannath, W.³ Posch, M.⁴

24
- 33845892180
- Change from baseline and analysis of covariance revisited
- Senn, S, Change from baseline and analysis of covariance revisited. Stat Med 25 (2006), 4334–4344.
- (2006) Stat Med , vol.25 , pp. 4334-4344
- Senn, S.¹

25
- 85062789466
- Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States
- published online Feb 3.
- Boye, KS, Riddle, MC, Gerstein, HC, et al. Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States. Diabetes Obes Metab, 2019 published online Feb 3. DOI:10.1111/dom.13649.
- (2019) Diabetes Obes Metab
- Boye, K.S.¹ Riddle, M.C.² Gerstein, H.C.³

26
- 84948740668
- Lixisenatide in patients with type 2 diabetes and acute coronary syndrome
- Pfeffer, MA, Claggett, B, Diaz, R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373 (2015), 2247–2257.
- (2015) N Engl J Med , vol.373 , pp. 2247-2257
- Pfeffer, M.A.¹ Claggett, B.² Diaz, R.³

27
- 85030448557
- Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
- Holman, RR, Bethel, MA, Mentz, RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 377 (2017), 1228–1239.
- (2017) N Engl J Med , vol.377 , pp. 1228-1239
- Holman, R.R.¹ Bethel, M.A.² Mentz, R.J.³

28
- 85058571092
- GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data
- Sposito, AC, Berwanger, O, de Carvalho, LSF, Saraiva, JFK, GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data. Cardiovasc Diabetol, 17, 2018, 157.
- (2018) Cardiovasc Diabetol , vol.17 , pp. 157
- Sposito, A.C.¹ Berwanger, O.² de Carvalho, L.S.F.³ Saraiva, J.F.K.⁴

29
- 85042126799
- Glucagon-like peptide-1 receptor agonists and cardiovascular events: class effects versus individual patterns
- Lim, S, Kim, KM, Nauck, MA, Glucagon-like peptide-1 receptor agonists and cardiovascular events: class effects versus individual patterns. Trends Endocrinol Metab 29 (2018), 238–248.
- (2018) Trends Endocrinol Metab , vol.29 , pp. 238-248
- Lim, S.¹ Kim, K.M.² Nauck, M.A.³

30
- 85060988178
- Protection against stroke with glucagon-like peptide 1 receptor agonists: a systematic review and meta-analysis
- Barkas, F, Elisaf, M, Milionis, H, Protection against stroke with glucagon-like peptide 1 receptor agonists: a systematic review and meta-analysis. Eur J Neurol 26 (2019), 559–565.
- (2019) Eur J Neurol , vol.26 , pp. 559-565
- Barkas, F.¹ Elisaf, M.² Milionis, H.³

31
- 85068568021
- Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
- published online June 10.
- Gerstein, HC, Colhoun, HM, Dagenais, GR, et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet, 2019 published online June 10. http://dx.doi.org/10.1016/S0140-6736(19)31150-X.
- (2019) Lancet
- Gerstein, H.C.¹ Colhoun, H.M.² Dagenais, G.R.³

32
- 85065306608
- Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus
- Zelniker, TA, Wiviott, SD, Raz, I, et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation 139 (2019), 2022–2031.
- (2019) Circulation , vol.139 , pp. 2022-2031
- Zelniker, T.A.¹ Wiviott, S.D.² Raz, I.³